Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition

Autoimmune toxicities, while common following treatment with cancer immunotherapies, are not well-characterized in patients treated with BRAF/MEK inhibitors. Emerging data suggest that autoimmune effects may be linked with superior responses to both treatment modalities; however, there is little evi...

Descripción completa

Detalles Bibliográficos
Autores principales: Knochelmann, Hannah M., Ware, Michael Brandon, Rali, Aditya, Linderman, Susanne, Shantha, Jessica G., Lawson, David H., Yushak, Melinda, Swerlick, Robert, Paulos, Chrystal M., Yeh, Steven, Kudchadkar, Ragini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008700/
https://www.ncbi.nlm.nih.gov/pubmed/35433480
http://dx.doi.org/10.3389/fonc.2022.836845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008700/
https://www.ncbi.nlm.nih.gov/pubmed/35433480
http://dx.doi.org/10.3389/fonc.2022.836845

Ejemplares similares